Last reviewed · How we verify
NCT05614726
A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study
NA trial testing 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase in Microbiota in 52 participants. Completed in 17 March 2022.
17 March 2022
Quick facts
| Lead sponsor | The Center for Applied Health Sciences, LLC |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 52 |
| Start date | 18 June 2021 |
| Primary completion | 17 March 2022 |
| Estimated completion | 17 March 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Conditions studied
- Microbiota — all drugs for Microbiota →
- Constipation — all drugs for Constipation →
- Candida — all drugs for Candida →
Sponsor
The Center for Applied Health Sciences, LLC
Who can join
Adults 30 to 60, any sex, with Microbiota or Constipation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, placebo-controlled, double-blind study will determine the effect of daily supplementation with a probiotic blend in 60 apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e., The Center for Applied Health Sciences). Subjects will attend three study visits. During Visit 1, subjects will be screened for participation \[i.e., medical history, routine blood work, background baseline diet\]. During Visits 2 and 3 subjects will complete questionnaires that assess their gastrointestinal health (e.g., abdominal discomfort/bloating, constipation, regularity, stool consistency). Visits 2 and 3 will correspond to before (week 0) and after six weeks of supplementation, respectively, with the probiotic dietary supplement or placebo.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A probiotic amylase blend reduces gastrointestinal symptoms in a randomised clinical study.
La Monica MB, Raub B, Lopez HL, Ziegenfuss TN. · · 2023 · cited 4× · PMID 38350481 · DOI 10.1163/18762891-20230043 -
A Probiotic Amylase Blend Positively Impacts Gut Microbiota Modulation in a Randomized, Placebo-Controlled, Double-Blind Study.
Ghannoum MA, Elshaer M, Al-Shakhshir H, Retuerto M, et al · · 2024 · PMID 39063578 · DOI 10.3390/life14070824
Verify or expand the search:
- PubMed search for NCT05614726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Microbiota
Currently open trials in the same condition.
- NCT07479511 — Adaptation of Lung Transplant Recipients at Extreme Altitude · active not recruiting
- NCT07212361 — Infant Microbiota Restoration With Maternal Microbes · NA · recruiting
- NCT07029360 — Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy · NA · recruiting
- NCT06809660 — Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (P · NA · recruiting
- NCT07154173 — Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer · recruiting
Other The Center for Applied Health Sciences, LLC trials
Trials by the same sponsor.
- NCT06700785 — A Pharmacokinetic Comparison of Three Butyrate Products · NA · completed
- NCT06106620 — Effects of a Multi-Ingredient Dietary Supplement on Blood and Breath Alcohol Levels · NA · completed
- NCT06062186 — Acute Effects of Naturally Occurring Tea and Coffee-based Ingredients on Cognitive Performance · NA · completed
- NCT06048640 — Effects of Dynamine Ingestion on Various Indices of Sustained Energy · NA · completed
- NCT05657314 — Effects of Pea Proteins on Muscle Damage and Recovery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05614726 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Center for Applied Health Sciences, LLC
- Last refreshed: 14 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05614726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing